DVA
72
2
NAVI
41
-3
CVS
48
3
WMT
74
2
MKC
56
8
NOV
58
3
SRE
63
-3
C
58
-2
TEL
60
2
CAH
47
3
ZBH
60
-2
KMX
58
3
VLO
40
-2
EFX
32
2
HSIC
54
-3
V
60
-6
AFL
46
-3
TGT
25
-24
USB
50
2
COP
56
2
DVA
72
2
NAVI
41
-3
CVS
48
3
WMT
74
2
MKC
56
8
NOV
58
3
SRE
63
-3
C
58
-2
TEL
60
2
CAH
47
3
ZBH
60
-2
KMX
58
3
VLO
40
-2
EFX
32
2
HSIC
54
-3
V
60
-6
AFL
46
-3
TGT
25
-24
USB
50
2
COP
56
2
Financhill
Back

Myriad Genetics 10K Form

Sell
16

MYGN
Myriad Genetics

Last Price:
14.97
Seasonality Move:
18.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08 10Q MYGN/Myriad Genetics Quarterly
2023-11-07 10Q MYGN/Myriad Genetics Quarterly
2023-08-04 10Q MYGN/Myriad Genetics Quarterly
2023-05-04 10Q MYGN/Myriad Genetics Quarterly
2022-11-02 10Q MYGN/Myriad Genetics Quarterly
2022-08-05 10Q MYGN/Myriad Genetics Quarterly

Receive MYGN News And Ratings

See the #1 stock for the next 7 days that we like better than MYGN

MYGN Financial Statistics

Sales & Book Value

Annual Sales: $753.2M
Cash Flow: $-5.6M
Price / Cash Flow: 0
Annual Sales: $8.04
Price / Book: 1.89

Profitability

EPS (TTM): -1.30000
Net Income (TTM): $-116M
Gross Margin: $517M
Return on Equity: -15.68%
Return on Assets: -10.41%

Myriad Genetics Earnings Forecast

Key Myriad Genetics Financial Ratios

  • The Gross Profit Margin over the past 28 years for MYGN is 68.64%.
  • The Selling, General & Administrative Expenses for MYGN have been equal to 76.06% of Gross Profit Margin.
  • The Research & Development expenses have been 11.78% of Revenue.
  • The Interest Expense is -1.10% of Operating Income.
  • The Net Earning history of MYGN is -34.96% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Myriad Genetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MYGN
CUSIP: 62855J
Website: myriad.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.9
Quick Ratio: 1.46

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 93.66

MYGN Technical Analysis vs Fundamental Analysis

Sell
16
Myriad Genetics (MYGN) is a Sell

Is Myriad Genetics a Buy or a Sell?

  • Myriad Genetics stock is rated a Sell
    The current Myriad Genetics [MYGN] share price is $15.30. The Score for MYGN is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.